Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(20%)

Phase Distribution

Ph phase_2
4
80%
Ph phase_3
1
20%

Phase Distribution

0

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 4 finished

Non-Completion Rate

100.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Terminated(4)
Other(1)

Detailed Status

Withdrawn3
Terminated1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (80.0%)
Phase 31 (20.0%)

Trials by Status

terminated120%
suspended120%
withdrawn360%

Recent Activity

0 active trials
Showing 5 of 5
withdrawnphase_2

Talabostat in Treating Patients With Metastatic Kidney Cancer

NCT00489710
withdrawnphase_2

Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

NCT00101140
suspendedphase_3

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00324831
withdrawnphase_2

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

NCT00112879
terminatedphase_2

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

NCT00066417

Clinical Trials (5)

Showing 5 of 5 trials
NCT00489710Phase 2

Talabostat in Treating Patients With Metastatic Kidney Cancer

Withdrawn
NCT00101140Phase 2

Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Withdrawn
NCT00324831Phase 3

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Suspended
NCT00112879Phase 2

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Withdrawn
NCT00066417Phase 2

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Terminated

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5